Well at the very least Sun Hung Kai and Mr Yap's Rockwell...

Well at the very least Sun Hung Kai and Mr Yap's Rockwell holdings know the value.
I expect to also see a SS Notice from Sun Hung Kai - they are increasing their holdings as well.

Sun Hung Kai has Lincoln Chee on the board

I suspect we wont see a move to have a new Director appointed from Mr Yap till Mr Yap has 19+ %, Obviously less than 20%.

The more he buys at prices around the $1.00 - 1.10 mark the better for him.
Also when he has say 48 Million shares you must remember their is no way out, his Modus-Operandi would be to wait for the buy out, unless he has no good intentions and wants to buy in order to sell its assets himself with the help of others.

FastenyourSeatbelt, not all Asian names are Chinese mate, some are also
Malaysian.....................Ect

Cash $180m
Debt $ 0m

Royalities $ 80m

Sub Total $ 260m

Pipeline Value assumption at some time in the future.
ART 621 $164m $219m
PMX53 $ 68m $ 84m
PMX-AMD $ 56m $103m
ART101 $ 21m $ 27m
ART104 $ 21m $ 33m
ART010 $ 19m $ 27m
ART150 $ 5m $ 7m
ART140 $ 5m $ 8m
ART160 $ 5m $ 5m
Sub Total $444m Low End
Sub Total $593m High end

Platforms Technology Value assumption
Superhumanisation $ 20m
Synhumanistaion $ 20m
EvoGene $ 20m
Sub Total $60m

Lucrative Partnership Deals Value assumption
Aveo 1st Product Milestones $2m Royalities @ 4% $20m
Aveo 2nd Product Milestones $2m Royalities @ 4% $20m
Aveo 3rd Product Milestones $2m Royalities @ 4% $20m
Aveo 4th Product Milestones $2m Royalities @ 4% $20m
Aveo 5th Product Milestones $2m Royalities @ 4% $20m

Vengenics 1 Product Milestones $2m Royalities @ 4% $20m

CSL Limited 1st Product Milestones $2m Royalities @ 4% $20m
CSL Limited 2nd Product Milestones $2m Royalities @ 4% $20m

GSK 1st Product Milestones $2m Royalities @ 4% $20m
GSK 2nd Product Milestones $2m Royalities @ 4% $20m
GSK 3rd Product Milestones $2m Royalities @ 4% $20m

Sub Total $22m Milestones
Sub Total $220m Royalities


So a sum of parts calculation could look something like this.

Low End High End
Cash $180m $180m
Royalities $ 80m $ 80m
Grants $ 7m $ 7m
PipeLine $364m $513m
Platforms $ 60m $ 60m
Partnerships $242m $242m

Total $ 933m $1082m


COMPARE THE TWO

ARANA – market cap today is $ 244 Million
Arana has 7 products in development
1 in the clinic.
1 in collaboration with Kyowa.
Arana has 11 in Partnership deals with Milestone and royalties expected on sales.
Arana has 3 technology platforms.

DOMANTIS – Sold for GBP 230 Million this equates to A$575 Million
Domantis had 5 products in development
None in the Clinic.
9 in partnership deals.
And 1 technology platform, this I could be wrong on.

Well is Arana undervalued,, anyone